Gilead Sciences

Open: 74.67 Close: 74.7 Change: 0.03

Try an AI to get informed about investing in Gilead Sciences.

The game is changing. There is a new strategy to evaluate Gilead Sciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, stock, GILD, Buy, price, year, …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences has outperformed the S&P 500 with a 19% return since August last year. Geoff Meacheram has given his Buy rating to Gileads due to several key reasons. The company is a publicly traded company.

Today's News

Gilead Sciences has outperformed the S&P 500 with a 19% return since August last year. The stock market is building up to a major ‘buy signal to be replaced’ Gilead Sciences - GILD - Stock Price Today - Zacks Is It Time to Buy GILD? Shares are down today. Shares are currently trading at $74.70. Gilead Sciences stock price is 74.74 USD today. The Gileade Sciences stock quote is 74.74. The company is a publicly traded company. There is only enough remdesivir to treat 200,000 patients worldwide, according to the drugs maker, Gilead Sciences. The latest price target is 74.85 per cent. Geoff Meacham from Bank of America Securities maintained Gilead Sciences ( GILD – Research Report ) to a Buy, with a price target of $95.00. Geoff Meacheram has given his Buy rating to Gileads due to several key reasons. Gilead has been taking on health challenges like HIV for more than 35 years. Appeals court invalidates $1.2 billion fine against Gilead Sciences. EY estimates that the COVID-19 impact on Phase 3 will be minimal. Fight stigma, wear red, share your story or selfie. #WorldAIDSDay 29 1,292 1,215 Gilead Sciences @GileadSciences · Dec 1, 2017. Add your photo to the #WorldADSDay #redribbon mosaic. Gilead Mexico was recently recognized as a best place to work for the #LGBTQ community by the @HRC. Gilead signs non-exclusive voluntary licensing agreements with five generic manufacturers.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

This document will help you to evaluate Gilead Sciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, stock, GILD, Buy, price, year, and the most common words in the summary are: gilead, science, stock, market, hiv, gileadsciences, price, . One of the sentences in the summary was: Geoff Meacheram has given his Buy rating to Gileads due to several key reasons. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #stock #market #hiv #gileadsciences #price.